FoxO1 negatively regulates cellular antiviral response by promoting degradation of IRF3

Cao-Qi Lei, Yu Zhang, Tian Xia, Li-Qun Jiang, Bo Zhong, and Hong-Bing Shu*
State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China

Running Title: FoxO1 promotes IRF3 degradation

*Address correspondence to: Hong-Bing Shu, College of Life Sciences, Wuhan University, Wuhan 430072, China; Email: shuh@whu.edu.cn; Tel: 86-27-68753795; Fax: 86-27-68753780

Background: The transcription factor IRF3 is critical for type I interferon induction and innate antiviral immune response.

Results: FoxO1 mediates IRF3 ubiquitination and degradation.

Conclusion: FoxO1 is a negative regulator of cellular antiviral response.

Significance: Our study reveals a new mechanism for control of type I interferon induction and cellular antiviral response.

Viral infection causes activation of the transcription factor IRF3, which is critical for production of type I interferons (IFNs) and innate antiviral immune response. How virus-induced type I IFN signaling is controlled is not fully understood. Here we identified the transcription factor FoxO1 as a negative regulator for virus-triggered IFN-β induction. Overexpression of FoxO1 inhibited virus-triggered ISRE activation, IFN-β induction as well as cellular antiviral response, whereas knockdown of FoxO1 had opposite effects. FoxO1 interacted with IRF3 in a viral infection-dependent manner and promoted K48-linked polyubiquitination and degradation of IRF3 in the cytosol. Furthermore, FoxO1-mediated degradation of IRF3 was independent of the known E3 ubiquitin ligases for IRF3, including RBCK1 and RAUL. Our findings thus suggest that FoxO1 negatively regulates cellular antiviral response by promoting IRF3 ubiquitination and degradation, providing a previously unknown mechanism for control of type I IFN induction and cellular antiviral response.

Introduction

Viral infection triggers a series of cellular signaling events that consequently lead to the production of type I interferons (IFNs). Type I IFNs further activate expression of many downstream genes, the products of which are involved in the inhibition of viral replication and clearance of infected cells (1,2).

During viral infection and replication process, viral molecular features called pathogen associated molecular patterns (PAMPs) such as single-stranded (ss) RNA, double-stranded (ds) RNA, and dsDNA...
are generated. Host pattern recognition receptors (PRRs) detect these PAMPs and initiate signaling cascades that induce expression of type I IFNs. The membrane associated receptor Toll-like receptor (TLR) 3 recognizes dsRNA and triggers TRIF-mediated signaling pathways that lead to the activation of type I IFNs (3-5). Cytosolic receptors such as RIG-I and MDA5 also act as viral RNA sensors. Upon the recognition of viral RNA, RIG-I and MDA5 undergo conformational change and interact with downstream mitochondrial-localized adapter protein VISA (also known as MAVS, Cardif and IPS-1) via their N-terminal CARD domains (6-9). Another mitochondria-and endoplasmic reticulum (ER)-localized adapter protein MITA (also known as STING) interacts with VISA and recruits downstream kinase TBK1 and transcription factor IRF3 to the VISA-associated complex, thereby promoting activation of IRF3 and expression of type I IFNs (10,11). Recently, we have found that GSK3β is required for IRF3-mediated type I IFNs induction via activation of TBK1 (12).

IRF3 is a member of the transcription factor family called interferon-regulatory factor (IRF). After activation, IRF3 translocates from cytosol to the nucleus, binds to conserved enhancer motifs called ISREs or IRF-Es in the promoters and initiates transcription of a number of genes such as IFNB1 and IFNA (13). The activation of IRF3 is tightly controlled by posttranscriptional modifications. The upstream kinases TBK1 and IKKe phosphorylate IRF3, which is required for its dimerization and activation. Many molecules, such as WDR5, TRIM56, MIB1/2 and TRIM32 are involved in this process by various mechanisms (14-17). IRF3 is sumoylated or desumoylated by viral or host components, which interferes with its activity and stability (18,19). While Herc5-mediated ISG15 modification of IRF3 positively regulates its activation (20), RBCK1 and RAUL are E3 ubiquitin ligases that induce K48-linked ubiquitination and degradation of IRF3, thereby turning down expression of type I IFNs (21,22). Whether and how other molecules are involved in regulating this process is of great interest.

FoxO1 (Forkhead box protein O1) belongs to the Fork-head transcription factor family that has a conserved DNA-binding domain termed as “forkhead box”. It has been reported that FoxO transcription factors are involved in many signaling pathways and regulate numerous cellular progresses, including tumor development, nervous system, metabolism, longevity, autophagy, and insulin action (23-26). Recently, FoxO3 was reported to inhibit IRF7 transcription and negatively regulate innate immune response (27). In this study, we identified FoxO1 as a negative regulator of virus-induced type I IFNs signaling pathways. FoxO1 was associated with IRF3 in a viral infection-dependent manner and promoted K48-linked polyubiquitination and degradation of IRF3, thereby inhibiting excessive expression of IFN-β and cellular antiviral response. Our findings thus uncovered a negative feedback regulatory mechanism of cellular antiviral response by FoxO1.

**Experimental Procedures**
Constructs
ISRE, NF-κB, IFN-β and IRF1 promoter luciferase reporter plasmids, mammalian expression plasmids for HA- or Flag-tagged IRF3 were previously described (11,12,18). Mammalian cDNA expression plasmids were purchased from Origene company. Flag- and HA-tagged FoxO1 and its mutants were constructed by standard molecular biology techniques. Flag-tagged VISA, MITA, Tbk1 and IKKe were previously described (11,12).

Reagents and antibodies
Recombinant human IFN-β (PeproTech), mouse monoclonal antibodies against Flag, HA and β-actin (Sigma), mouse polyclonal antibody against GFP and rabbit polyclonal antibody against IRF3 (Santa Cruz Biotechnology), rabbit polyclonal antibodies against FoxO1 (Cell Signaling Technology) were purchased from the indicated manufacturers. SeV, VSV, NDV-GFP and VSV-GFP were previously described (17,28).

Transfection and Reporter Gene Assays
293 cells (~1×10^5) were seeded on 24-well plates and transfected on the following day by standard calcium phosphate precipitation method. In the same experiment, empty control plasmid was added to ensure that each transfection receives the same amount of total DNA. To normalize for transfection efficiency, 0.01 µg of pRL-TK Renilla luciferase reporter plasmid was added to each transfection. Luciferase assays were performed using a dual-specific luciferase assay kit (Promega) and the firefly luciferase activities were normalized based on Renilla luciferase activities.

Coimmunoprecipitation, Ubiquitination and Western Blot Analysis
These experiments were performed as described (6,11,12).

Real-time PCR
Total RNA was isolated from cells using Trizol reagent (TAKARA, Japan) and subjected to real-time PCR analysis to measure expression of mRNA. The mRNA levels of specific genes were normalized to GAPDH mRNA. Gene-specific primer sequences were as following:
IFNB1:
TTGTGAGAACCCTCCTGGCT (forward),
TGACTATGTCAGGACACAG (reverse);
CCL5:
GGCAGCCCTCGCTGTCATCC (forward),
GCAGCAGGGGTGGTGTCCG (reverse);
ISG56:
TCATCAGGTCAAGATAGTC (forward),
CCACACTGTATTTGGTGTCTTAGG (reverse);
ISG15:
AGGACAGGGGTCCCCCTTGCC (forward),
CCTCCAGCCCGCTCACTTGC (reverse);
GAPDH:
GAGTCAACGGGATTTGGTCTCTG (forward),
GACAAGCTTCCCGGTCTCAG (reverse).

by guest on March 23, 2020http://www.jbc.org/Downloaded from
**VSV Plaque Assays**
Cells were grown in 24-well plate and transfected with the indicated plasmids. Twenty-four hours after transfection, cells were transfected by Lipoactamine with poly (I:C) (1 µg) or control buffer for another 24 hours prior to VSV infection. At 1 hour post-infection, cells were washed with warm PBS and then fresh medium was added. The supernatant was harvested 24 hours later and used to infect confluent cultured Vero cells. Plaque assays were then performed as described (11,12).

**Virus manipulation**
Cells were grown in 24-well plates and transfected with the indicated plasmids prior to virus infection. The culture medium was replaced by serum-free DMEM containing NDV-GFP or VSV-GFP viruses (MOI = 0.1). One hour later, the cells were washed with PBS and then fed with DMEM containing 10% FBS. NDV-GFP or VSV-GFP replication was visualized by monitoring the GFP expression level in fluorescence microscopy or by western immunoblot analysis.

**Size-exclusion chromatography**
Cells (1×10^7) were lysed in 1.2 ml lysis buffer. The lysate was centrifuged for 0.5 hours at 15,000 r.p.m. The supernatant was recovered and loaded onto a Superdex 200 gel filtration chromatography column pre-equilibrated with lysis buffer. The samples were eluted from the column in lysis buffer at a flow rate of 0.5 ml/min and collected in fractions of 0.5 ml. The fractions were precipitated with 20% trichloroacetic acid and analyzed by Western blots with antibodies against IRF3 and FoxO1, respectively.

**RNAi**
Double-strand oligonucleotides corresponding to the target sequences were cloned into the pSuper.Retro RNAi plasmid (Oligoengine Inc.). The following sequences were targeted for human FoxO1 and RAUL cDNA respectively: FoxO1-RNAi: #1: CCTCATGGATGGAGATACA; #2: CTCAAATGCTAGTACTATT; #3: CTGCATCCATGGACAACAA; #4: CCATGGACAACACAGTAA. RAUL-RNAi: GCAAGAAGTCAAGGAGAT.
The Non-specific-RNAi and pGCSIL-FoxO1-RNAi were provided by Dr. Wei-Guo Zhu (Peking University) and previously described (23). The pSuper-RBCK1-RNAi was previously described (21).

**Results**

**Overexpression of FoxO1 inhibits virus-triggered IFN-β induction**
To identify candidate molecules involved in virus-triggered IFN-β induction, we screened ~15,000 independent human and mouse cDNA expression plasmids by IFN-β promoter luciferase reporter assays and found that human FoxO1 (clone 45A1) inhibited Sendai virus (SeV)-induced activation of the IFN-β promoter (Figure S1A). To further confirm this result, we made Flag-tagged expression plasmid encoding human FoxO1 independently of the clone 45A1 and performed additional luciferase reporter assays. As shown in Figure 1A, overexpression of Flag-FoxO1 strongly inhibited
SeV-induced activation of ISRE, NF-κB and the IFN-β promoter in a dose-dependent manner. Results from real-time PCR experiments indicated that overexpression of FoxO1 inhibited SeV-induced expression of downstream genes, such as IFNB1 and CCL5 (Figure 1B). Poly(I:C), a synthetic analog of viral dsRNA, is recognized by TLR3 on the membrane or RLR in the cytoplasm, respectively. We found that overexpression of FoxO1 potently inhibited poly(I:C)-triggered both RLR- (Figure 1C) and TLR3- (Figure 1D) mediated activation of the IFN-β promoter and ISRE. This effect is not cell-type specific because overexpression of FoxO1 also inhibited SeV-induced activation of the IFN-β promoter in HCT116 and HeLa cells (Figure 1E). In similar reporter assays, overexpression of FoxO1 did not affect IFN-γ-triggered activation of IRF1 promoter and SeV-triggered activation of AP-1 (Figure S1B and S1C). Furthermore, overexpression of FoxO1 did not affect IFN-β-induced expression of RIG-I or MDA5 (Figure S1D). These data suggest that FoxO1 specifically inhibits virus-triggered induction of downstream genes.

**Knockdown of FoxO1 potentiates SeV-induced expression of IFNB1**

We next determined whether endogenous FoxO1 was involved in virus-triggered IFN-β induction. We constructed four RNAi plasmids (pSuper-FoxO1-RNAi #1 - #4) and obtained a previously reported RNAi plasmid (pGCSIL-FoxO1-RNAi) (23) for FoxO1, all of which could inhibit the expression of transfected and endogenous FoxO1 (Figure 2A). In reporter assays, knockdown of FoxO1 potentiated SeV-induced activation of IFN-β promoter, ISRE and NF-κB in 293 cells (Figure 2B and 2C). Consistently, results from real-time PCR experiments confirmed that SeV-induced expression of IFNB1 was increased by knockdown of FoxO1 (Figure 2D). In addition, knockdown of FoxO1 potentiated cytosolic poly(I:C)-induced activation of IFN-β promoter, but did not affect IFN-γ-induced activation of the IRF1 promoter (Figure S2A and S2B). These results suggest that endogenous FoxO1 inhibits virus-triggered IFN-β expression.

We further found that knockdown of FoxO1 could potentiate SeV- but not IFN-β-triggered expression of RIG-I and MDA5 (Figure S2C and S2D), indicating that FoxO1 functions in virus-triggered type I IFNs signaling rather than downstream of type I IFNs. Because FoxO1 negatively regulated virus-triggered IFN-β expression, we next determined whether FoxO1 was involved in the regulation of cellular antiviral response. In plaque assays with vesicular stomatitis virus (VSV), we found that knockdown of FoxO1 significantly inhibited VSV replication and further promoted cytoplasmic poly(I:C)-mediated inhibition of VSV replication (Figure 2E). Similarly, the replication of GFP-tagged VSV and Newcastle disease virus (NDV) was inhibited in FoxO1-knockdown cells compared with control cells as monitored by GFP expression (Figure 2F and S2E). To examine whether FoxO1 regulates viral replication directly by interfering the replication machinery or indirectly by regulating type I IFNs, we determined the effects
of FoxO1-RNAi on virus replication in VISA-knockdown cells, in which viral infection-induced expression of type I IFNs was impaired. The results showed that viral replication was comparable between cells transfected with VISA-RNAi alone and those with both VISA-RNAi and FoxO1-RNAi (Figure S2F), indicating that FoxO1 negatively regulates viral replication indirectly through type I IFNs. Collectively, these results suggest that endogenous FoxO1 plays a key role in the regulation of type I IFN production and cellular antiviral response.

FoxO1 negatively regulates virus-triggered signaling at IRF3 level

A series of components have been reported to participate in virus-triggered IFN-β induction, such as RIG-I, VISA, MITA, TBK1 and IRF3. To determine the molecular order of FoxO1 in the regulation of virus-triggered IFN-β induction, we transfected plasmids encoding these molecules together with the IFN-β promoter or ISRE reporters in the presence or absence of FoxO1, and found that FoxO1 could markedly inhibit activation of the IFN-β promoter and ISRE mediated by overexpression of IRF3 and the upstream adaptors or kinases, including VISA, MITA and TBK1 (Figure 3A and 3B). Conversely, knockdown of FoxO1 potentiated ISRE activation mediated by IRF3 and the upstream molecules (Figure 3C). These results indicate that FoxO1 functions at the level or downstream of IRF3 for regulation of virus-triggered IFN-β expression.

FoxO1 is associated with IRF3 in a viral infection-dependent manner

Because FoxO1 is a transcription factor that functions at the level or downstream of IRF3, we hypothesized that FoxO1 might interact with IRF3 and interfere its transcriptional activity. In transient transfection and co-immunoprecipitation experiments, overexpression of FoxO1 interacted with IRF3 constitutively (Figure 4A). We further found that GFP-tagged IRF3 colocalized with cherry-FoxO1 by confocal immunofluorescent microscopy analysis (Figure S3A). In our gel filtration experiments, we found that FoxO1 and IRF3 were mostly isolated in different fractions (IRF3, lanes 6-8 and lanes 17-20; FoxO1, lanes 9-11 and lanes 12-15) in uninfected cells (Figure 4B). After viral infection, increased FoxO1 and IRF3 were detected in overlapping fractions (lanes 8-11) (Figure 4B), suggesting that viral infection may induce FoxO1 and IRF3 complex formation. Consistent with these observations, results from endogenous co-immunoprecipitation experiments indicated that FoxO1 did not interact with IRF3 without stimulation but was associated with IRF3 at 8 hours after SeV infection (Figure 4C). These results suggest that FoxO1 interacts with IRF3 in a viral infection-dependent manner.

Previously, it has been reported that FoxO1 shuttles between cytosol and nucleus after activation (29,30). We next determined the localization of FoxO1 in cells in response to viral infection. Surprisingly, cherry-tagged FoxO1 was mainly localized in the cytosol (Figure S3A). We then performed cellular fractionation and immunoblot analysis and found that endogenous FoxO1 was mainly localized in the cytosol and barely detectable in the nucleus in the
presence or absence of SeV infection in 293 cells (Figure 4D). Previously, it has been reported that FBS could retain FoxO1 and FoxO3 (another member of Fork-head transcription factor) in the cytosol. In our experiments, we found that there was increased FoxO1 in the nucleus in the absence of FBS and viral infection resulted in translocation of FoxO1 from the nucleus to cytosol (Figure S3B). Interestingly, SeV-induced activation of IFN-β promoter was inhibited and potentiated by overexpression or knockdown of FoxO1 in the absence of FBS, respectively (Figure S3C and S3D). We next determined whether FoxO1 interacts with IRF3 in the cytosol or nucleus. As shown in Figure 4E, FoxO1 interacted with IRF3 in the cytosol after viral infection. These data collectively suggest that FoxO1 interacts with IRF3 in the cytosol in a viral infection-dependent manner.

**FoxO1 targets IRF3 for degradation**

When examining the interaction between FoxO1 and IRF3, we repeatedly observed that overexpression of FoxO1 resulted in a decreased level of IRF3 (Figure 4A and S4A). We thus hypothesized that FoxO1 might regulate the stability of IRF3 protein. To test this hypothesis, we co-transfected Flag-tagged FoxO1 together with HA-tagged IKKε, VISA, MITA or IRF3 and performed immunoblot analysis. As shown in Figure 5A, FoxO1 specifically down-regulated the amount of IRF3 protein. In similar experiments, FoxO1 down-regulated the expression of IRF3-5A and IRF-5D, which are inactive and active mutants of IRF3 respectively (Figure S4A). Our experiments indicated that FoxO1 also down-regulated IRF7, which forms dimer with IRF3 and activates IFN expression, but had minimal effects on IRF5 level (Figure S4B). We also found that overexpression of FoxO1 promoted degradation of endogenous IRF3 with or without viral infection (Figure 5B), whereas knockdown of FoxO1 delayed the degradation of IRF3 after SeV infection (Figure 5C and S4C). In addition, knockdown of FoxO1 resulted in increased level of IRF7 after SeV infection (Figure S4D). In contrast, unlike FoxO3-mediated transcriptional inhibition of IRF7, FoxO1 did not affect transcription of IRF3 in the presence or absence of SeV infection (Figure 5D). These data demonstrate that FoxO1 negatively regulates IRF3 at protein level.

To further confirm this conclusion, we treated cells with actinomycin-D and CHX, which are inhibitors of transcription or protein synthesis, respectively, and examined the half-life of IRF3 protein in the presence or absence of FoxO1. As shown in Figure S4E and S4F, overexpression of FoxO1 significantly accelerated degradation of IRF3 in cells treated with actinomycin-D or CHX. FoxO1-mediated degradation of IRF3 could be restored by treatment with the proteasome inhibitor MG132 but not with the autophagy inhibitor 3-MA (Figure 5E and S4G). These data indicate that FoxO1 controls half-life of IRF3 protein in a proteasome-dependent manner.

**FoxO1 promotes K48-linked ubiquitination and degradation of IRF3**

Having established that FoxO1
negatively regulates virus-triggered IFN-β activation by promoting IRF3 degradation in a proteasome-dependent pathway, we next examined the role of FoxO1 in regulating ubiquitination of IRF3. As shown in Figure 5F, overexpression of FoxO1 potentiated ubiquitination and degradation of IRF3. Because K48-linked polyubiquitin modification leads to the target proteins for proteasome recognition and degradation, we determined whether FoxO1 promoted K48- or K63-linked ubiquitination of IRF3. As shown in Figure 5G, overexpression of FoxO1 significantly increased K48-linked but not K63-linked ubiquitination of IRF3. We further examined whether endogenous FoxO1 played a role in regulating virus-triggered IRF3 ubiquitination. As shown in Figure 5H, ubiquitination of IRF3 was strongly increased after SeV infection, which was diminished in FoxO1-knockdown 293 cells. Previous studies have identified several E3 ubiquitin ligases that catalyze K48-linked ubiquitination of IRF3, including RBCK1 and RAUL (21,22). However, knockdown of neither RBCK1 nor RAUL had any effect on FoxO1-mediated inhibition of SeV-triggered activation of ISRE or degradation of IRF3 (Figure S5A and S5B). Conversely, RBCK1- or RAUL-mediated inhibition of SeV-triggered ISRE activation or degradation of IRF3 did not require FoxO1 (Figure S5C and S5D), indicating that FoxO1 mediates degradation of IRF3 via an unknown E3 or a different mechanism that involves the ubiquitin-proteasome system. Taken together, these results suggest that FoxO1 promotes K48-linked polyubiquitination and proteasome-dependent degradation of IRF3.

**Discussion**

Viral infection leads to production of type I IFNs that are responsible for inhibition of virus replication, clearance of virus-infected cells, and facilitation of adaptive immune response. However, uncontrolled and excessive immune response causes pathological immunity to the host. To prevent harmful effects during acute infection, host cells have developed distinct strategies to control excessive innate immune response. In the present study, we identified the transcription factor FoxO1 as a negative feedback regulator of innate cellular antiviral response.

Our results demonstrated that FoxO1 specifically inhibited virus-triggered expression of type I IFNs and the cellular antiviral response. Overexpression of FoxO1 inhibited virus-triggered activation of the IFN-β promoter and ISRE in various types of cells, whereas knockdown of FoxO1 potentiated virus-triggered IFN-β induction and ISRE activation and inhibited viral replication. Interestingly, neither overexpression nor knockdown of FoxO1 had effect on IFN-β-induced expression of RIG-I or MDA5. Taken together these data suggest that FoxO1 physiologically restricts virus-triggered type I IFN signaling and cellular antiviral response.

To explore the mechanisms by which FoxO1 regulates virus-triggered type I IFN induction, we first examined the molecular order of the involvement of FoxO1 in this process and found that FoxO1 regulated ISRE activation at the
level or downstream of IRF3. Considering FoxO1 is a transcription factor, we hypothesized that FoxO1 might interact with IRF3 and interfere with its transcriptional activity. However, our study demonstrated that FoxO1 interacted with IRF3 in the cytosol at 8 hours after virus infection, excluding the possibility that FoxO1 interferes with the transcriptional activity of IRF3 in the nucleus. Our study also showed that the protein level of FoxO1 was increased at 8-12 hours after viral infection, while the mRNA level of FoxO1 remained unaltered after SeV infection for indicated times (Figure S6A), indicating that viral infection triggers a posttranscriptional regulation of FoxO1. In this context, it is possible that viral infection-induced up-regulation of FoxO1 in the cytosol accounts for FoxO1-IRF3 association after viral infection. How FoxO1 protein was increased by viral infection requires further investigations.

Interestingly, we routinely observed that overexpression of FoxO1 specifically resulted in decreased protein level of IRF3 but had no effect on the mRNA level of IRF3, indicating that FoxO1 regulates the stability of IRF3 protein. Furthermore, overexpression of FoxO1 did not affect the ratio of phosphorylated IRF3 to the total IRF3 (pIRF3:IRF3) after SeV infection, though the levels of phosphorylated IRF3 and total IRF3 were dramatically decreased, indicating that FoxO1 does not regulates the IRF3 phosphorylation. It should be noted that the basal level of IRF3 was higher in 293 cells transfected with FoxO1-RNAi than controls. There are several reasons behind this phenomenon. First, FoxO1 may interact with IRF3 weakly and induce degradation of IRF3 under steady condition, which is beyond our detection limit. In this context, we found that a small part of IRF3 and FoxO1 were co-isolated from the same fractions in our gel filtration experiments. Second, FoxO1 may have additional targets which could destabilize IRF3 without virus infection. Nonetheless, our data clearly demonstrates that FoxO1 interacts with and promotes degradation of IRF3 after viral infection.

Protein stability is regulated by proteasome-mediated degradation or autophagy-mediated protein hydrolysis. In our experiments, we found that FoxO1-mediated degradation of IRF3 was inhibited by the proteasome inhibitor MG132 but not by the autophagy inhibitor 3-MA. In addition, FoxO1 promoted K48-linked ubiquitination of IRF3 and knockdown of FoxO1 strongly inhibited virus-induced ubiquitination and degradation of IRF3. Previously, it has been reported that several E3 ubiquitin ligases such as RBCK1 and RAUL induce ubiquitination and degradation of IRF3 (21,22). However, neither of them was involved in FoxO1-mediated degradation of IRF3, indicating that FoxO1 and these E3s function independently and/or redundantly for regulation of IRF3. Future studies are required to identify the potential E3 ubiquitin ligase that is responsible for FoxO1-mediated IRF3 degradation and to fully elucidate the mechanisms by which FoxO1 restricts virus-triggered type I IFN induction and cellular antiviral response. Nonetheless, our results clearly demonstrate that FoxO1 regulates IRF3 stability through
ubiquitin-proteasome system after viral infection.

FoxO1 has recently been reported to regulate regulatory T (T_{reg}) cell development in the thymus and deficiency of FoxO1 in T_{reg} cells renders mice severe autoimmune diseases (31). In this study, we found that FoxO1 is important for control of excessive immune response by regulating turnover of IRF3. Thus, our study not only provides new insight into the molecular mechanisms for termination of excessive immune responses, but also provides a potential target for drug development against viral infection-related and autoimmune diseases.

Acknowledgements
We thank Dr. Yan-Yi Wang (Wuhan Institute of Virology), Yu Liu and Shu Li (Wuhan University) for discussions. We also thank Dr. Wei-Guo Zhu for reagents. This work was supported by grants from the Chinese Ministry of Science and Technology (2012CB910201, 2010DFA31100), the National Science Foundation of China (91029302, 31130020 and 31221061), the Chinese 111 project (B06018), and the academic award for excellent Ph.D. Candidates funded by Ministry of Education of China.

Reference
1. Akira, S., Uematsu, S., and Takeuchi, O. (2006) Cell 124, 783-801
2. Hiscott, J. (2007) Cytokine Growth Factor Rev 18, 483-490
3. Alexopoulou, L., Holt, A. C., Medzhitov, R., and Flavell, R. A. (2001) Nature 413, 732-738
4. Han, K. J., Su, X., Xu, L. G., Bin, L. H., Zhang, J., and Shu, H. B. (2004) J Biol Chem 279, 15652-15661
5. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T. (2003) Nat Immunol 4, 161-167
6. Xu, L. G., Wang, Y. Y., Han, K. J., Li, L. Y., Zhai, Z., and Shu, H. B. (2005) Mol Cell 19, 727-740
7. Seth, R. B., Sun, L., Ea, C. K., and Chen, Z. J. (2005) Cell 122, 669-682
8. Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., and Tschopp, J. (2005) Nature 437, 1167-1172
9. Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K. J., Takeuchi, O., and Akira, S. (2005) Nat Immunol 6, 981-988
10. Ishikawa, H., and Barber, G. N. (2008) Nature 455, 674-678
11. Zhong, B., Yang, Y., Li, S., Wang, Y. Y., Li, Y., Diao, F., Lei, C., He, X., Zhang, L., Tien, P., and Shu, H. B. (2008) Immunity 29, 538-550
12. Lei, C. Q., Zhong, B., Zhang, Y., Zhang, J., Wang, S., and Shu, H. B. (2010) Immunity 33, 878-889
13. Au, W. C., Moore, P. A., Lowther, W., Juang, Y. T., and Pitha, P. M. (1995) Proc Natl Acad Sci U S A 92, 11657-11661
14. Wang, Y. Y., Liu, L. J., Zhong, B., Liu, T. T., Li, Y., Yang, Y., Ran, Y., Li, S., Tien, P., and Shu, H. B. (2010) Proc Natl Acad Sci U S A 107, 815-820
15. Tsuchida, T., Saitoh, T., Kawai, T., Abe, T., Matsuura, Y., W., and Akira, S. (2010) Immunity 33, 765-776
16. Li, S., Wang, L., Berman, M., Kong, Y. Y., and Dorf, M. E. (2011) Immunity 35, 426-440
Conflict of interest
The authors declare that they have no conflict of interest.

Figure Legends

Figure 1. Overexpression of FoxO1 inhibits virus-triggered induction of downstream genes.
(A) FoxO1 inhibits SeV-induced activation of ISRE, NF-κB and IFN-β promoter in a dose-dependent manner. The 293 cells (1×10⁵) were transfected with the IFN-β promoter, ISRE and NF-κB luciferase reporter (0.1 μg) and the indicated amounts of Flag-FoxO1 plasmids. Twenty hours after transfection, cells were infected with SeV or left uninfected for 10 hours before reporter assays were performed.
(B) FoxO1 inhibits SeV-induced expression of IFNBI and CCL5 genes. The 293 cells (4×10⁵) were transfected with control or FoxO1 expression plasmids (2 μg each) for 20 hours. Cells were then infected with SeV or left uninfected for 10 hours before real-time PCR analysis was performed.
(C) FoxO1 inhibits cytosolic poly(I:C)-triggered activation of the IFN-β promoter and ISRE. The 293 cells (1×10^5) were transfected with control or FoxO1 expression plasmids (0.25 µg) and the indicated reporter plasmids (0.1 µg). Twenty hours after transfection, cells were mock-transfected or transfected with poly(I:C) (1 µg) for 16 hours before luciferase assays were performed.

(D) FoxO1 inhibits TLR3-mediated activation of the IFN-β promoter and ISRE. The 293-TLR3 cells (1×10^5) were transfected with FoxO1 expression (0.5 µg) and the indicated reporter (0.1 µg each) plasmids. Twenty hours after transfection, cells were treated with poly(I:C) (50 µg/ml) or left untreated for 12 hours before luciferase assays were performed.

(E) FoxO1 inhibits SeV-induced activation of the IFN-β promoter in HCT116 or HeLa cells. The experiments were performed as in (A) except that HeLa cells and HCT116 cells were used.

Figure 2. Knockdown of FoxO1 potentiates SeV-induced expression of IFN-β

(A) Effects of FoxO1-RNAi plasmids on the expression of transfected FoxO1. Left panels: the 293 cells (4×10^5) were transfected with expression plasmids for Flag-FoxO1 and HA-β-actin (0.1 µg each), and the indicated RNAi plasmids (2 µg). Twenty-four hours after transfection, cell lysates were analyzed by immunoblot with anti-HA and anti-Flag. Right panels: the 293 cells (4×10^5) were transfected with control or the indicated FoxO1-RNAi plasmids (2 µg each). Thirty-six hours later, cells were lysed and the cell lysates were analyzed by immunoblot with the indicated antibodies. NS-RNAi, Non-specific RNAi; pFoxO1-RNAi, pGCSIL-FoxO1-RNAi.

(B) Effects of FoxO1-RNAi plasmids on SeV-induced activation of the IFN-β promoter. The 293 cells (1×10^5) were transfected with the indicated FoxO1-RNAi (0.5 µg) and IFN-β reporter (0.1 µg) plasmids. Thirty-six hours after transfection, cells were left uninfected or infected with SeV for 10 hours before luciferase assays were performed.

(C) Knockdown of FoxO1 potentiates SeV-induced ISRE and NF-κB activation. The experiments were performed as in (B) except that the ISRE and NF-κB reporter was used.

(D) Effects of FoxO1-RNAi plasmids on SeV-induced expression of IFNBI gene. The 293 cells (4×10^5) were transfected with control or FoxO1-RNAi plasmids (3 µg). Thirty-six hours after transfection, cells were left uninfected or infected with SeV for 10 hours before real-time PCR analysis was performed.

(E) Effects of FoxO1-RNAi on VSV replication. The 293 cells (1×10^5) were transfected with the pFoxO1-RNAi plasmids (0.5 µg each). Thirty-six hours later, cells were mock-transfected or transfected with poly(I:C) (1 µg) for 16 hours and then infected with VSV (MOI=0.1). The supernatants were harvested 24 hours after infection for standard plaque assays.

(F) Effects of FoxO1-RNAi on VSV-GFP replication. The 293 (1×10^5) cells were transfected with pFoxO1-RNAi plasmids (1 µg). Thirty-six hours later, cells were infected with VSV-GFP (MOI=0.1) for 24 hours and imaged by microscopy or
analyzed by immunoblots with the indicated antibodies. The amounts of VSV-GFP were quantitated using the Bio-Rad Quantity One Program and were normalized to that of β-actin.

Figure 3. FoxO1 negatively regulates SeV-induced activation of ISRE at IRF3
(A) Overexpression of FoxO1 inhibits VISA-, MITA-, TBK1- and IRF3 (5D)-mediated IFN-β promoter activation. The 293 cells (1×10⁵) were transfected with control or FoxO1 expression plasmids and the indicated plasmids (0.1 μg each). Reporter assays were performed 24 hours after transfection. Expression of transduced proteins were detected by immunoblot with indicated antibodies.

(B) Overexpression of FoxO1 inhibits VISA-, MITA-, TBK1- and IRF3-mediated ISRE activation. The experiments were performed as in (A) except that the ISRE reporter was used.

(C) Knockdown of FoxO1 potentiates VISA-, IKKε-, TBK1- and IRF3-mediated ISRE activation. The 293 cells (1×10⁵) were transfected with control or FoxO1-RNAi plasmids (0.5 μg). Thirty-six hours later, cells were further transfected with the indicated plasmids (0.1 μg each) and ISRE reporter plasmids. Reporter assays were performed 24 hours after transfection.

Figure 4. FoxO1 interacts with IRF3 in a viral infection-dependent manner
(A) FoxO1 interacts with IRF3. The 293 cells (2×10⁶) were transfected with the indicated plasmids. Twenty hours after transfection, co-immunoprecipitation was performed with anti-HA or control IgG. The immunoprecipitates were analyzed by immunoblot with anti-Flag (upper panel). The lysates were analyzed by immunoblots with anti-Flag or anti-HA (lower panels).

(B) Analysis of protein complexes containing FoxO1 and IRF3 by size-exclusion chromatography. The 293 cells (1×10⁷) were infected with SeV for 8 hours or left uninfected before lysis. Cell lysates were analyzed by size-exclusion chromatography on Superdex 200 column. The individual fractions were analyzed by Western blots with anti-FoxO1 and anti-IRF3 antibodies, respectively.

(C) Endogenous FoxO1 interacts with IRF3 after viral infection. The 293 cells (1×10⁷) were left uninfected or infected with SeV for the indicated time points. Cells were lysed and the lysates were immunoprecipitated with anti-IRF3 or control IgG. The immunoprecipitates were analyzed by immunoblot with anti-FoxO1 (upper panel). The expression levels of the endogenous FoxO1, IRF3 and β-actin were analyzed by immunoblot analysis (lower panels).

(D) Immunoblot analysis of the subcellular fractions. The 293 cells were infected with SeV for the indicated time points. Cell fractionations were performed and the fractions were analyzed by immunoblots with the indicated antibodies (upper four panels). The whole cellular levels of FoxO1 and IRF3 upon viral infection were analyzed by immunoblots with indicated antibodies (lower three panels).

(E) FoxO1 interacts with IRF3 in the cytosol. The 293 cells (1×10⁷) were left uninfected or infected with SeV for 8 hours. Cell fractionations were performed as in (C). The fractions were immunoprecipitated with anti-IRF3. The
immunoprecipitates were analyzed by immunoblot with anti-FoxO1 (upper panel). The expression levels of the endogenous FoxO1 and IRF3 were detected by immunoblot analysis (lower four panels).

Figure 5. FoxO1 promotes K48-linked ubiquitination and degradation of IRF3
(A) FoxO1 specifically destabilizes IRF3. The 293 (4x10^5) cells were transfected with the indicated plasmids for 20 hours before immunoblot analysis was performed with the indicated antibodies.
(B) Overexpression of FoxO1 destabilizes endogenous IRF3. The 293 cells (4x10^5) were transfected with control or FoxO1 expression plasmids (3 µg). Twenty hours after transfection, cells were left uninfected or infected with SeV for 8 hours before immunoblot analysis was performed with the indicated antibodies. The amounts of pIRF3 were quantitated using the Bio-Rad Quantity One Program and were normalized to that of IRF3.
(C) Knockdown of FoxO1 delays the degradation of IRF3 following viral infection. The 293 cells (4x10^5) were transfected with control or pFoxO1-RNAi plasmids (3 µg). Thirty-six hours after transfection, cells were left uninfected or infected with SeV for the indicated time points before immunoblot analysis was performed with the indicated antibodies.
(D) Effect of FoxO1 on IRF3 gene transcription. The 293 cells (4x10^5) were transfected with FoxO1 expression or FoxO1-RNAi plasmids (2 µg). Twenty-four or thirty-six hours after transfection, cells were left uninfected or infected with SeV for 8 hours. Cells were then harvested for real-time PCR analysis.
(E) FoxO1 mediates IRF3 degradation in a proteasome-dependent manner. The 293 cells (4x10^5) were transfected with the indicated plasmids (0.5 µg each) and the indicated amounts of FoxO1 expression plasmid. Twenty hours later, cells were treated with MG132 (10 µM) for 6 hours before immunoblot analysis was performed.
(F) Overexpression of FoxO1 promotes ubiquitination of IRF3. The 293 cells (2x10^6) were transfected with the indicated plasmids. Twenty hours after transfection, cell lysates were denatured and immunoprecipitated with anti-Flag and the immunoprecipitates were analyzed by immunoblot with anti-Myc (upper panel). The expression levels of the proteins were examined by immunoblots with the indicated antibodies (lower panels).
(G) FoxO1 mediated K48-linked ubiquitination of IRF3. The 293 cells (2x10^6) were transfected with the indicated plasmids. Twenty hours after transfection, cell lysates were denatured. The lysates were analyzed by immunoprecipitation with anti-Flag and immunoblots with the anti-HA (upper panel) antibodies. The levels of the transfected proteins were examined by immunoblots with the anti-HA (middle panels) and anti-Flag (lower panels) antibodies, respectively. K48, ubiquitin with all lysines except K48 were mutated; K63, ubiquitin with all lysines except K63 were mutated.
(H) Effect of FoxO1-RNAi on SeV-induced ubiquitination of IRF3. The 293 cells (1x10^7) were transfected with control or pFoxO1-RNAi plasmids. Thirty-six
hours after transfection, cells were left uninfected or infected with SeV for 8 hours. Cells were lysed and the lysates were immunoprecipitated with anti-IRF3. The immunoprecipitates were analyzed by immunoblot with anti-ubiquitin (upper panel). The expression of the related proteins was examined by immunoblots with the anti-FoxO1 (middle panels) and anti-β-actin (lower panels) antibodies, respectively.
Lei et al., Fig. 1
Lei et al., Fig. 2

A

B

C

D

E

F

IFNB1

MOI=0.1

Mock
dpoly(I:C)

NS pFoxO1-RNAi

Rel. GFP intensity: 1 0.21
Lei et al., Fig. 3

A

IFN-β

|              | Vec | FoxO1 |
|--------------|-----|-------|
| Rel. Luc. Act. |  |       |
| Vec          |  |  |
| VISA        |  |  |
| MITA       |  |  |
| TBK1       |  |  |
| IRF3       |  |  |
| lysate      |  |  |

B

ISRE

|              | Vec | FoxO1 |
|--------------|-----|-------|
| Rel. Luc. Act. |  |       |
| Vec          |  |  |
| VISA        |  |  |
| MITA       |  |  |
| TBK1       |  |  |
| IRF3       |  |  |
| lysate      |  |  |

C

ISRE

|              | NS | pFoxO1-RNAi |
|--------------|----|-------------|
| Rel. Luc. Act. |   |             |
| Vec          |  |  |
| VISA        |  |  |
| TBK1       |  |  |
| IKKe       |  |  |
| IRF3       |  |  |
| lysate      |  |  |

by guest on March 23, 2020http://www.jbc.org/Downloaded from
Lei et al., Fig 4

A

| IP: IgG αHA | IgG αHA | IB: αFoxO1 |
|------------|---------|------------|
| HA-IRF3    | Vec Flag-FoxO1 |
| lysate     | -Flag-FoxO1 |

B

| SeV (hr): | 0 | 0 | 4 | 8 |
|-----------|---|---|---|---|
| IP: IgG αIRF3 |
| lysate     | -IRF3 |
| lysate     | -FoxO1 |
| lysate     | -β-actin |

C

D

| nucleus | cytosol |
|---------|---------|
| SeV: 0 2 4 8 12 24 |
| IB: αFoxO1 |
| IB: αIRF3 |
| IB: LMNB1 |
| IB: β-actin |

E

| cytosol | nucleus |
|---------|---------|
| SeV: - + - + |
| IP: IgG αIRF3 |
| lysate |
| lysate |
| lysate |
| lysate |
FoxO1 negatively regulates cellular antiviral response by promoting degradation of IRF3

Cao-Qi Lei, Yu Zhang, Tian Xia, Li-Qun Jiang, Bo Zhong and Hong-Bing Shu

J. Biol. Chem. published online March 26, 2013

Access the most updated version of this article at doi: 10.1074/jbc.M112.444794

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2013/03/26/M112.444794.DC1